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Objective: To investigate the in vitro and in vivo radiosensitization effect of an institutionally 
designed nanoliposome encapsulated cisplatin (NLE-CDDP).
Materials and methods: NLE-CDDP was developed by our institute. In vitro radiosensitization 
of NLE-CDDP was evaluated by colony forming assay in A549 cells. In vivo radiosensitization was 
studied with tumor growth delay (TGD) in Lewis lung carcinoma. The radiosensitization for 
normal tissue was investigated by jejunal crypt survival. The radiosensitization studies were car-
ried out with a 72 h interval between drug administration and irradiation. The mice were treated 
with 6 mg/kg of NLE-CDDP or CDDP followed by single doses of 2 Gy, 6 Gy, 16 Gy, and 28 
Gy. Sensitization enhancement ratio (SER) was calculated by D0s of cell survival curves for 
A549 cells, doses needed to yield TGD of 20 days in Lewis lung carcinoma, or D0s of survival 
curves in crypt cells in radiation alone and radiation plus drug groups.
Results: Our NLE-CDDP could inhibit A549 cells in vitro with half maximal inhibitory concen-
tration of 1.12 µg/mL, and its toxicity was 2.35 times that observed in CDDP. For in vitro studies 
of A549 cells, SERs of NLE-CDDP and CDDP were 1.40 and 1.14, respectively, when combined 
with irradiation. For in vivo studies of Lewis lung carcinoma, the strongest r  adiosensitization 
was found in the 72 h interval between NLE-CDDP and irradiation. When given 72 h prior to 
irradiation, NLE-CDDP yielded higher radiosensitization than CDDP (SER of 4.92 vs 3.21) and 
slightly increased injury in jejunal crypt cells (SER of 1.15 vs 1.19). Therefore, NLE-CDDP 
resulted in a higher TGF than did CDDP (4.28 vs 2.70) when SERs were compared between 
experiments in vivo and in jejunal crypt cell studies.
Conclusions: Our NLE-CDDP was demonstrated to have radiosensitization with TGF of 4.28 
when administrated 72 h prior to irradiation.
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Introduction
Cisplatin (CDDP) is a highly effective antitumor agent and is applied widely in the 
treatment of various cancers. Furthermore, CDDP is a commonly used radiosensitizer. 
However, after intravenous injection, the majority of CDDP is bound with plasma 
albumin to form an essentially irreversible complex with limited antitumor activity. 
In addition, the renal toxicity of CDDP limits its use. Therefore, it is important to study 
how to avoid or reduce plasma albumin binding of CDDP and improve its effective 
bioavailability.1–3
Liposome technologies, especially the long-circulating nanoliposome t  echnologies, 
provide effective means to solve those problems.4,5 Liposomal CDDP can isolate agents 





of free CDDP in blood. Nanoliposome can penetrate the 
interendothelial cell gap of nascent tumor capillaries much 
easier than of normal tissues, then deposit in the tumor. Those 
natural characteristics can increase CDDP concentration in 
the tumor while reducing CDDP concentration in normal 
tissues, thereby decreasing its toxicity.6–8 In this study, we 
investigated the radiosensitization effect in vitro and in vivo 




NLE-CDDP was produced in the School of Pharmacy, 
  Shanghai Jiao Tong University, Shanghai, People’s 
R  epublic of China, by the reverse-phase evaporation 
method, which was originally introduced by Szoka and 
  Papahadjopoulos.9 The lipid agents included hydrogenated 
soybean p  hosphatidylcholine (HSPC, NOF corporation, 
Tokyo, Japan), cholesterol (Sigma-Aldrich, St Louis, MO), 
and 2000PEG-1, 2-distearoyl-sn-glycero-3-phosphoeth-
anolamine (2000PEG-DSPE, NOF Corporation). CDDP 
was packed in central aqueous core of the liposomal nano-
particles at a ratio of 1:5 (CDDP vs lipid molar). The final 
NLE-CDDP consisted of small nanoliposomes of an average 
size of approximately 100 nm with CDDP concentration of 
1 mg/mL. The formulation was stable at room temperature. 
The CDDP remained at a concentration of 93% of the initial 
status even 1 month after preparation. In this study, NLE-
CDDP was prepared immediately prior to use. CDDP was 
taken as the control, which was obtained from Shandong Qilu 
Pharmaceutical Company (Lot number 060924).
cell culture
A549 human lung adenocarcinoma cell line was used in 
this study, incubated in RPMI medium 1640 (GIBCO®, 
Invitrogen, Gaithersburg, MD) with 10% fetal bovine serum 
(Biochrom, Berlin, Germany) at 37°C in a humidified atmo-
sphere of 5% CO2. Logarithmic growth cells were harvested 
for experiments.
Methylthiazoltetrazolium (MTT) assay
A549 cells were seeded in 96-well plates with a density 
of 3000 cells/90 µL per well and incubated overnight. 
  NLE-CDDP and CDDP solutions were prepared with RPMI 
1640 medium without serum and added to the cells, 10 µL per 
well, with final drug concentrations of 0.1 µg/mL, 0.3 µg/mL, 
0.5 µg/mL, 1 µg/mL, 3 µg/mL, 5 µg/mL, and 10 µg/mL in 
medium, respectively. Eight replicates were performed for 
each drug dose. Every well plate had two controls: saline and 
culture medium. After cells were incubated for 48 h, 20 µL 
3-(4, 5-  dimethylthiazol-2-y1)-2, 5-diphenytetrazolium bromide 
was added in each well and remained for 4 h. Then 100 µL solu-
bilization solution was added into the medium. The absorbance 
of the colored solution was quantified by a spectrophotometer at 
570 nm with a reference wavelength of 630 nm. Inhibition of cell 
viability was calculated by the formula: [1 - (ODtest - ODblank)/
(ODcontrol - ODblank)], and half maximal inhibitory concentration 
(IC50) was derived from GraphPad Prism. Free liposomes were 
also tested for cell inhibition by MTT.
colony forming assay
A549 cells were incubated in 25 cm2 flasks overnight then 
exposed to NLE-CDDP or CDDP at a concentration of 
0.5 µg/mL, or irradiated. Drugs were administrated 24 h 
before irradiation. Cells were irradiated using a 6 MV X-ray 
linear accelerator at a dose rate of 1.24 Gy/min. Two hours 
after irradiation, cells were trypsinized, counted, and seeded in 
6 cm dishes with 5 mL medium at a  ppropriate c  oncentrations. 
There were three dishes at each dose. The cells were incubated 
for 10 days and then stained with c  rystal violet. Colonies with 
more than 50 cells were counted. Cell   survival curve was esti-
mated by a multitarget single-hit model (S = 1 - (1 - e-D/D0)N) 
(L-Q) and then D0 was calculated.
In vivo tumor inhibition test
The in vivo study was approved by the Animal Study 
Committee and was conducted in accordance with Fudan 
University guidelines and regulations on the use and care of 
laboratory animals. Lewis lung carcinoma was implanted 
in the right flank of C57BL/6N male mice (6 weeks old 
and weight 17 ± 1.8 g). Mice were purchased from the 
Experimental Animal Center, Chinese Academy of Sciences, 
Shanghai, and maintained in specific pathogen-free rooms. 
The in vivo study was started 5 to 7 days after implantation 
when flank tumors grew to diameters of 8–10 mm.
Lewis lung carcinoma-bearing mice were randomly 
assigned to one of the following groups: CDDP alone, 
NLE-CDDP alone, irradiation alone, CDDP followed by 
i  rradiation, NLE-CDDP followed by irradiation, and control 
with no treatments. Drugs were injected through the mouse 
tail vein at a dose of 6 mg/kg. In order to investigate whether 
NLE-CDDP can enhance the radiation effect even after a 
long time, we designed experiments with different intervals 
between drug administration and irradiation. A single dose 
of 6 Gy irradiation was delivered 1 h, 24 h, and 72 h after 





group, single doses of 0 Gy, 2 Gy, 6 Gy, 16 Gy, and 28 Gy 
were given in the irradiation-alone and combination of 
irradiation and drugs groups.
Tumors were measured three times a week until the death 
of the mice or 60 days after treatment. Tumor volume was 
calculated by V = (a*b2)/2, where a was the maximum diam-
eter and b was the orthogonal diameter. However, a relative 
tumor volume was used, which was a ratio of tumor volume 
after treatment versus the pretreatment volume. Tumor growth 
curves were constructed according to the Gompertz model 
with the equation y = V0*exp(k*(1 - exp(-a*X ))), where V0 
was the original tumor volume; k and a, coefficient; X, irra-
diation dose, and y tumor growth delay (TGD) time. TGD 
in days was defined as the difference between T5V0 of treated 
tumors compared with untreated tumors. T5V0 was the days 
needed for tumor growth from the original size to five times 
its original volume.
enhancement of irradiation  
injury in intestinal epithelium
A total of 75 mice was divided into three groups: radiation 
alone, CDDP and radiation, and NLE-CDDP and radiation. 
Each group included five subgroups that received total abdo-
men irradiation of 0 Gy, 8 Gy, 10 Gy, 12 Gy, and 14 Gy, 
respectively. Irradiation was carried out 72 h after NLE-
CDDP or CDDP injection. The mice were sacrificed 3.5 days 
after irradiation. Then a segment of jejunum was removed 
and its transverse slices were sectioned for hematoxylin 
and eosin staining. The number of crypts per circumference 
was counted under microscope, and crypt survival was then 
calculated. The jejunal crypt survival curves were deter-
mined by linear-quadratic model (L-Q) with the   equation 
y = exp (-α*D - β*D2), where α and β were coefficient; 
D, i  rradiation dose; and y, survival faction. Sensitization 
enhancement ratio (SER) was the ratio of β value of the 
combination to radiation alone group.
statistics
Comparisons of mean value were performed by   Student’s 
t-test and one-way analysis of variance (ANOVA). 
C  omparisons of tumor growth were performed using 
repeated-measures ANOVA. The impact of irradiation and 
drugs on tumor growth was analyzed by the general linear 
model, and the differences among groups were compared 
by the Games–Howell method. The significance level was 
set at P , 0.05.
For A549 cells, SER was defined as the ratio of D0 in 
radiation alone over D0 in the drugs and radiation groups. 
The biological endpoint was defined as a TGD of 20 days 
for in vivo Lewis lung carcinoma, and SER was the ratio of 
radiation dose needed to reach the endpoint in the irradiation 
alone versus irradiation dose in combination groups. SER 
was the ratio of D0 in the radiation alone group over D0 in 
the drugs and radiation group for jejunal crypt.
Results
NLe-cDDP and cDDP  
cytotoxicity in vitro
No toxicity was detected in A549 cell line for free liposomes, 
whereas the survivals trend increased compared with that in 
the control group. Both NLE-CDDP and CDDP demonstrated 
inhibitions of A549 cells (Figure 1). IC50 of NLE-CDDP 
and CDDP was 1.12 µg/mL and 2.63 µg/mL, respectively. 
  NLE-CDDP was more toxic than CDDP when drug con-
centrations were 3 µg/mL (P , 0.05), whereas when the 
concentrations increased to 5 µg/mL and 10 µg/mL, both 
drugs showed similar inhibition.
In vitro colony forming assay
Cell survival curves are illustrated in Figure 2. D0s was 
1.406 Gy, 1.235 Gy, and 1.005 Gy, respectively for the 
irradiation-alone, CDDP plus irradiation, and NLE-CDDP 
plus irradiation groups. SERs of CDDP and NLE-CDDP 
were 1.14 and 1.40, respectively (P = 0.043).
In vivo drug radiosensitization when 
combined with 6 gy at different intervals
Tumor growth curves are shown in Figure 3 and TGD in 
Table 1. Irradiation of 6 Gy alone yielded a TGD of 1.83 days, 
which was significantly different from the control (P , 0.05). 






























Figure 1 effect of free liposomes, NLe-cDDP, and cDDP on A549 cells.





NLE-CDDP alone resulted in a longer TGD of 11.95 days 
rather than 3.27 days in CDDP. For combination groups, 
NLE-CDDP produced significantly longer TGD than CDDP 
did in 1 h, 24 h, and 72 h interval groups, with P values of 
0.000, 0.001, and 0.0003, respectively. Moreover, longer drug 
treatment time produced longer TGD, but statistical signifi-
cance was found only in the NLE-CDDP group between the 
1 h and 72 h treatment groups (P = 0.007). Variance analysis 
was performed and the impact of different intervals on TGD 
was statistically significant, with F of 6.610 and P value of 
0.000.
In vivo drug radiosensitization  
when combined with irradiation  
at 72 h interval
In this experiment the interval was 72 h when drugs and 
irradiation were combined. The tumor growth curves are 
shown in Figure 4 and TGD in Table 2. With an increase in 
irradiation dose, tumor growth became slow and TGD was 
gradually extended in the irradiation-alone, NLE-CDDP, 
and CDDP groups. Drug plus irradiation prolonged TGD 
but was more pronounced for NLE-CDDP and irradiation 
(P = 0.002).
Dose response curves were generated for the irradiation-
alone, NLE-CDDP plus irradiation, and CDDP plus irradiation 
with a 72 h interval in combination groups (Figure 5) from 
data in Table 2. In Figure 5 the curves are nearly p  arallel when 






















Figure 2 cell survival curves after treatments with radiation alone (r) or combined 
with 0.5 µg/mL NLe-cDDP (NLe-cDDP + r) or cDDP (cDDP + r) (P = 0.00 for 
cDDP vs r; P = 0.00 for NLe-cDDP vs r; P = 0.043 for cDDP vs NLe-cDDP).










































































































Figure 3 Tumor growth curves after irradiation of 6 gy, 6 mg/kg of NLe-cDDP or 
cDDP or combinations of 6 gy and NLe-cDDP/cDDP. A) Tumors treated with 
6 gy, NLe-cDDP, cDDP, or combinations of 6 gy and NLe-cDDP/cDDP with 
1 h interval between drugs and irradiation (P = 0.000). B) Tumors treated with 6 gy, 
NLe-cDDP, cDDP, or combinations of 6 gy and NLe-cDDP/cDDP with 24 h 
interval between drugs and irradiation (P = 0.000). (P = 0.001). C) Tumors treated 
with 6 gy, NLe-cDDP, cDDP, or combinations of 6 gy and NLe-cDDP/cDDP with 
72 h interval between drugs and irradiation (P = 0.000). (P = 0.0003). (relative tumor 
volume: a ratio of tumor volume after treatment versus the pretreatment volume.)
Abbreviations: cDDP, cisplatin; NLe-cDDP, nanoliposome encapsulated cisplatin.
Table 1 Tumor growth delay in Lewis lung carcinoma after NLe-
cDDP plus 6 gy or cDDP plus 6 gy with different intervals
Group T5V0 (days) TGD (days)
control 6.12 0
6 gy 7.95 1.83
NLe-cDDP 18.07 11.95
cDDP 9.39 3.27
NLe-cDDP-1 h-6 gy 18.33 12.21
NLe-cDDP-24 h-6 gy 19.16 13.04
NLe-cDDP-72 h-6 gy 26.97 20.85
cDDP-1 h-6 gy 10.85 4.73
cDDP-24 h-6 gy 11.11 4.99
cDDP-72 h-6 gy 12.77 6.65
Abbreviations: cDDP, cisplatin; NLe-cDDP, nanoliposome encapsulated cisplatin; 
TgD, tumor growth delay; T5V0, the days needed for tumor growth from the original 





TGDs were between 15 and 25 days. Thus, TGD of 20 days was 
taken as a biological endpoint. To achieve a TGD of 20 days, 
38.1 Gy, 24.83 Gy, and 7.74 Gy were needed, respectively, for 
the irradiation-alone, CDDP plus irradiation, and NLE-CDDP 
plus irradiation groups. Therefore, when drugs were admin-
istrated 72 h before radiation, SER was 3.21 (24.83/7.74) for 
CDDP and 4.92 (38.1/7.74) for NLE-CDDP.
Drug radiosensitization  
for jejunum crypt cells
Mice were sacrificed 3.5 days after treatment in order to count 
jejunum crypts. The number of survived jejunal crypts and 
survivals for each group are illustrated in Figure 6. When 
drugs were injected intravenously 72 h before irradiation, 
SERs were 1.15 for NLE-CDDP and 1.19 for CDDP based 
on the regression curves and L-Q model.
Therapeutic gain factor (TgF)
When drugs were used 72 h before irradiation, TGF was 4.28 
(4.92/1.15) for NLE-CDDP and 2.70 (3.21/1.19) for CDDP 








































































































Figure 4 Tumor growth curves treated with a single dose of irradiation, NLe-
cDDP plus irradiation, or cDDP plus irradiation with 72 h interval. A) Tumor 
treated with single doses of irradiation. B) Tumor treated with 6 mg/kg of NLe-
cDDP followed by irradiation. C) Tumor treated with 6 mg/kg of cDDP followed 
by irradiation.
Abbreviations:  cDDP,  cis-platinum  diammine  dichloride;  NLe-cDDP,  nanoli  po-
some encapsulated cisplatin.
Table 2 Tumor growth delay (days) in Lewis lung carcinoma 
after NLe-cDDP plus irradiation, or cDDP plus irradiation with 
72 h interval
Group 0 Gy 2 Gy 6 Gy 16 Gy 28 Gy
Irradiation-alone 0 0.4 1.83 1.99 7.48
NLe-cDDP + irradiation 11.95 15.29 20.85 19.54 56.88
cDDP + irradiation 3.27 3.96 6.65 13.38 21.98











(1−exp(−0.00019*x))) (R2 = 0.997)
y = 11.45587*exp(2.07548*
(1−exp(−0.04037*x))) (R2 = 0.883)
y = 3.61301*exp(2965.86811*




































Figure  5  Dose-response  curves  from  irradiation  combined  with  NLe-cDDP 
or cDDP administered 72 h prior to irradiation in Lewis lung carcinoma.
Abbreviations: cDDP, cis-platinum diammine dichloride; NLe-cDDP, nanoliposome 









































Figure 6 Jejunal crypt cell survivals after irradiation (r), combinations of cDDP and 
irradiation (cDDP + r), or NLe-cDDP and irradiation (NLe-cDDP + r) with 72 h 
interval. L-Q model: Irradiation alone: y = exp (0.18*d - 0.026*d2), R2 = 1.000 NLe-
cDDP + irradiation: y = exp(0.202*d - 0.03*d2), R2 = 0.980 cDDP + irradiation: 
y = exp(0.218*d - 0.031*d2), R2 = 0.999.
Abbreviations: cDDP, cis-platinum diammine dichloride; NLe-cDDP, nanoliposome 






Nanoliposomes have been widely studied in cancer 
  treatments as a vector to deliver chemicals into tumor cells, 
but clinically evident results were limited. The aim of the 
current study was to synthesize a new NLE-CDDP that could 
yield a higher tumor concentration and extended CDDP 
release, and to study its use in combination with radiation 
as a radiosensitizer.
Burger et al reported that NLE-CDDP could enhance 
the cytotoxicity and significantly increase cell death up 
to 1000 times, compared with the same concentration of 
CDDP.10 In our study, IC50 of CDDP against A549 cells 
was 2.35 times that of NLE-CDDP (2.63 µg/mL vs 
1.12 µg/mL), which was higher than the 1.34 times reported 
by Carvalho et al.11 In addition, in vivo tests also demon-
strated much stronger tumor inhibitions in NLE-CDDP than 
those in CDDP, indicating that the cytotoxicity of our NLE-
CDDP was more significant than the cytotoxicity of CDDP. 
The strong toxicity of NLE-CDDP may be attributed to its 
small size (100 nm), which is smaller than that reported in the 
literature (174 nm).11 Nanoliposome encapsulated CDDP in 
liposomes and prevented CDDP from immediately binding 
with proteins, then CDDP was gradually released directly 
to the tumor cells through adsorption, lipid exchange, 
e  ndocytosis, and fusion, by which cell killing was increased.12 
Ramachandran et al also found that the uptake of nanoparticle 
formations of CDDP by cells was much easier.13
CDDP is a radiation sensitizer and has been widely used 
with radiation therapy for cancer treatment.14 The mecha-
nism of CDDP enhancement of irradiation effect had been 
studied by Lu and Kalantari et al, who revealed that the 
cytotoxicity was enhanced by low-dose cisplatin combined 
with r  adiotherapy. The underlying mechanism was the 
electron-transfer reaction of cisplatin with electrons gener-
ated in ionizing irradiation.15,16 This finding was similar to 
what was found in hypoxic cell radiosensitizers, an electron 
affinity agent. In Lu’s study, a low dose of CDDP (50 µM) 
increased irradiation-induced single and double DNA strain 
breaks, resulting in more cell killing.
In clinical trials, a daily dose of CDDP before 
r  adiotherapy was thought to be the best way to improve 
the e  fficacy of radiotherapy, but it also caused the long 
duration of gastrointestinal tract symptoms.17 Therefore, 
although daily low-dose CDDP has a proven radiosensiti-
zation effect, its routine use in practice is limited because 
of its toxicities and i  nconvenience of administration via 
intravenous infusion.
Our NLE-CDDP developed in this study was prepared 
by reverse phase evaporation with a new formulation of 
sustained release CDDP (100 nm in size, modified by poly-
ethylene glycol on the surface), resulting in slow-release, 
passive targeting, and long-cycle characteristics. The lipid 
compositions of the liposome were nontoxic in vitro toxicity 
tests, suggesting that the liposomes could be potentially used 
in animals or humans safely.
Our in vitro study demonstrated that both CDDP and 
NLE-CDDP possessed radiosensitization properties. This 
was shown by smaller shoulder and slope of cell survival 
curves in CDDP/NLE-CDDP compared with those of irra-
diation alone. However, NLE-CDDP has a stronger radio-
sensitization effect than CDDP (SER of 1.40 vs 1.14). Our 
in vivo study of combination treatments confirmed that the 
interval between the delivery of NLE-CDDP and irradiation 
impacted tumor inhibition, with the strongest effect in 72 h 
intervals. Thus, in our in vivo radiosensitization study, we 
used a 72 h interval.
The in vivo study demonstrated that both CDDP and 
NLE-CDDP possessed radiosensitization with an SER of 
3.21 for CDDP and 4.92 for NLE-CDDP, indicating that 
NLE-CDDP had stronger radiosensitization. The stronger 
radiosensitization of NLE-CDDP was probably the benefit 
of its features of in vivo controlled release and passive 
t  argeting, which was consistent with the outcome in a slow-
release formulation of CDDP combined with radiation.18,19 
Our p  harmacokinetic study also demonstrated that free 
platinum in serum could remain at a concentration of 
1.04 µg/mL 72 h after injection of NLE-CDDP (6 mg/kg) 
through the tail vein, but it could not be detected only 2 h 
after CDDP administration, which suggests that NLE-
CDDP could extend in vivo circulation time and maintain 
a certain concentration for a long time.20 In addition, our 
previous study also confirmed the nanoparticle could 
aggregate in tumors passively, resulting in concentration 
of NLE-CDDP in tumors higher than that of CDDP.20 Due 
to its release function, our NLE-CDDP could be accumu-
lated in tumors and released slowly and continuously, like 
a drug delivery pump, thereby keeping the tumor exposed 
to drug continuously. When tumors were irradiated, the 
drugs deposited in tumors played the role of radiosensi-
tizer. In contrast, injected CDDP was quickly bound with 
proteins and excreted from the body, maintaining a low 
c  oncentration in tumor for a short time. This elucidates 
the potential underlying mechanism for the stronger 





It has been reported that CDDP increased irradiation 
i  njury.21 We used jejunal crypt cell assay to investigate 
whether our NLE-CDDP would increase toxicity. When com-
bined with irradiation, NLE-CDDP yielded lower survival 
of crypt cells than did irradiation alone, with SER of 1.15, 
whereas CDDP also sensitized irradiation injury of jejunal 
crypt cell with SER of 1.19. Nevertheless, NLE-CDDP did 
not show significant increased intestinal injury compared 
with CDDP. The explanation for less radiosensitization of 
NLE-CDDP for jejunal crypt cell than for tumors was due 
to the difference in drug distribution. NLE-CDDP could 
accumulate in tumors much easier than in normal tissues 
due to the enhanced permeability and retention (EPR) 
effect. EPR effect is a property by which certain sizes of 
molecules, typically liposomes or macromolecular drugs, 
tend to a  ccumulate in tumor tissue much more than they do 
in normal tissues.22–24 In general, tumor vessels are usually 
abnormal in form and architecture. They are poorly aligned 
defective en  dothelial cells with wide fenestrations, l  acking 
a smooth muscle layer or innervation with a wider lumen, 
and with impaired functional receptors for angiotensin II. 
All those factors will lead to abnormal molecular and fluid 
transport dynamics, especially for macromolecular drugs. 
The EPR effect helps to carry the nanoparticles and spread 
them in tumors. However, there is no EPR effect for normal 
tissue because of their normal vessels.
TGF was 4.28 for NLE-CDDP and 2.70 for CDDP in both 
SERs for Lewis lung carcinoma (in vivo) and jejunal crypt 
cell. Therefore, the NLE-CDDP developed in the current 
study showed its potential as a radiosensitizer in irradiation 
therapy and warrants further investigation.
In summary, NLE-CDDP could inhibit A549 cells in vitro 
with an IC50 of 1.12 µg/mL, and its toxicity was 2.35 times 
that of CDDP. When combined with irradiation, an in vitro 
study of A549 cell line confirmed its radiosensitization with 
SER of 1.40. An in vivo study showed that the strongest 
radiosensitization was found in the 72 h interval between 
NLE-CDDP and irradiation. When used 72 h prior to irra-
diation in Lewis lung carcinoma-bearing mice, NLE-CDDP 
yielded SER of 4.92. In both in vitro and in vivo studies, 
SERs were higher for NLE-CDDP than those for CDDP. 
NLE-CDDP also enhanced radiation injury to jejunal crypt 
cells with SER of 1.15, but TGF was 4.28.
Acknowledgments
This study was sponsored by a grant from the Shanghai 
Science and Technology Committee (nr 0552nm44). 
The authors thank Dr Jiade J Lu for his assistance in editing 
this article.
Disclosure
No conflicts of interest were declared in relation to this 
paper.
References
  1.  Stathopoulos  GP,  Boulikas T, Vougiouka  M,  Rigatosi  SK, 
  Stathopoulos JG. Liposomal CDDP combined with gemcitabine in 
pretreated advanced pancreatic cancer patients: A phase I-II study. 
Oncol Rep. 2006;15:1201–1204.
  2.  Xiao C, Qi XR, Maitani Y, Nagai T. Sustained release of CDDP from 
multivesicular liposomes: potentiation of antitumor efficacy against 
S180 murine carcinoma. J Pharma Sci. 2004;93(7):1149–1157.
  3.  Burger KNJ, Staffhorst RWHM, Vijlder HECD, et al. Nanocapsules: 
lipid-coated aggregates of CDDP with high cytotoxicity. Nat Med. 
2002;8(1):81–84.
  4.  Ramachandran S, Quiwt AP, Kumar S, Lal R. CDDP nanoliposomes 
for cancer therapy: AFM and fluorescence imaging of CDDP encap-
sulation, stability, cellular uptake, and toxicity. Langmuir. 2006;22: 
8156–8162.
  5.  Han I, Kim OJ, Lee GY, Sung YK, Song R, Sohn Y. Enhanced anti-
tumor activity of trans (1,2-Diaminocyclohexaneglutamatoplatinum 
(II)) formulated with stealth liposome. Bioorg Med Chem. 2003;11: 
5443–5447.
  6.  Rosenthal DI, Yom SS, Liu L, et al. A Phase I study of SPI-077 (Stealth 
liposomal CDDP) concurrent with radiation therapy for locally advanced 
head and neck cancer. Invest New Drugs. 2002;20:343–349.
  7.  Koukourakis MI, Coukouraki S, Giatromanolaki A, et al. Liposomal 
doxorubicin and conventionally fractionated radiotherapy in the treat-
ment of locally advanced non-small-cell lung cancer and head and neck 
cancer. J Clin Oncol. 1999;17:3512–3521.
  8.  Huang SK, Lee KD, Hong K, Friend DS, Papahadjopoulos D. 
M  icroscopic localization of sterically stabilized liposomes in colon 
carcinoma-bearing mice. Cancer Res. 1992;52:5135–5143.
  9.  Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes 
with large internal aqueous space and high capture by reverse–phase 
evaporation. Proc Natl Acad Sci. 1978;75(9):4194–4198.
  10.  Burger KN, Staffhorst RW, Velinova MJ, et al. Nanocapsules: 
  lipid-coated aggregates of CDDP with high cytotoxicity. Nat Med. 
2002;8(1):81–84.
  11.  Carvalho Júnior AD, Vieira FP, de Melo VJ, et al. Preparation and 
cytotoxicity of CDDP-containing liposomes. Braz J Med Biol Res. 
2007;40(8):1149–1157.
  12.  Jia W, Gao WY. New Formulations of Drug Controlled Release. Beijing: 
Chemical Industry Press; 2005:313.
  13.  Ramachandran S, Quist AP, Kumar S, et al. CDDP nanoliposomes for 
cancer therapy: AFM and fluorescence imaging of CDDP encapsula-
tion, stability, cellular uptake, and toxicity. Langmuir. 2006; 22(19): 
8156–8162.
  14.  Joschko MA, Webster LK, Bishop JF, et al. Radioenhancement by 
CDDP with accelerated fractionated radiotherapy in a human tumour 
xenograft. Cancer Chemother Pharmacol. 1997;40(6):534–539.
  15.  Lu QB. Molecular reaction mechanisms of combination treatment of 
low-dose cisplatin with radiotherapy and photodynamic therapy. J Med 
Chem. 2007;50:2601–2604.
  16.  Lu QB, Kalantari S, Wang CR. Electron transfer reaction mechanism of 
cisplatin with DNA at the molecular level. Mol Pharmaceutics. 2007; 
4(4):624–628.
  17.  Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of 
concomitant CDDP and radiotherapy on inoperable non-small cell lung 
cancer. N Engl J Med. 1992;326:524–530.International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.






  18.  Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Pegylated 
liposome-encapsulated doxorubicin and CDDP enhance the effect of 
radiotherapy in a tumor xennograft model. Clin Cancer Res. 2000;6: 
4939–4949.
  19.  Ning S, Yu N, Brown DM, Kanekal S, Knox SJ. Radiosensitization 
by intratumoral administration of CDDP in a sustained-release drug 
delivery system. Radiother Oncol. 1999;50:215–223.
  20.  Zhang XM, Ge YQ, Jiang GL, et al. Pharmacokinetics of CDDP 
p  ackaged in a nanometer liposome. China Oncol. 2007;17(11): 
715–718.
  21.  Douple EB, Eaton WL, Tulloh ME. Skin radiosensitization studies 
using combined cis-dichlorodiammineplatinum (II) and radiation. 
Int J Radiat Oncol Biol Phys. 1979;5(8):1383–1385.
  22.  Matsumura Y, Maeda H. A new concept for macromolecular therapeutics 
in cancer chemotherapy: mechanism of tumoritropic accumulation of 
proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1): 
6387–6392.
  23.  Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular perme-
ability and the EPR effect in macromolecular therapeutics: a review. 
J Control Release. 2000;65(1–2):271–284.
  24.  Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and 
  pharmacokinetic study of PK1 [N-(2-hydroxypropyl) m  ethacrylamide 
copolymer doxorubicin]: first member of a new class of c  hemotherapeutic 
agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II 
Committee. Clin Cancer Res.1999;5(1):83–94.